Semaglutide in Houston, with the workup it actually requires.
Sustainable weight loss with the longest-track-record GLP-1 medication — Wegovy or Ozempic, dosed to your labs and adjusted as your body responds, with physician oversight at every step.
A weekly GLP-1 injection with the longest track record in the category.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a once-weekly subcutaneous injection that reduces appetite, slows gastric emptying, and improves insulin sensitivity. FDA-approved as Wegovy for chronic weight management since 2021 and as Ozempic for type 2 diabetes since 2017, it has the longest real-world clinical history of any drug in its class.
For most patients starting GLP-1 therapy in 2026, semaglutide remains the first-line choice because the safety record is longer, the trial data is broader, and insurance coverage tends to be more accessible than newer alternatives. Tirzepatide produces somewhat greater weight loss in head-to-head data; some patients tolerate semaglutide better, others find tirzepatide easier. Both have their place.
The case for semaglutide, honestly.
Semaglutide isn’t always the strongest option for the largest weight loss — that’s tirzepatide. But for most patients starting GLP-1 therapy, semaglutide is where we begin. Here’s how we think about it.
Longest real-world history
FDA-approved as Ozempic since 2017 and as Wegovy for weight management since 2021. Millions of patient-years of post-market safety data. When something unexpected happens in this class of medications, it tends to show up in semaglutide first because the patient pool is biggest.
Evidence: Strong · Largest post-market datasetSELECT trial cardiac benefit
The SELECT trial (NEJM 2023) showed a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease — independent of weight loss. This is now an FDA indication, not just an off-label observation. Strongest CV outcomes data in the obesity drug class.
Evidence: Strong · SELECT trial, 17,604 patientsEasier insurance + savings programs
Wegovy and Ozempic have broader insurance coverage than newer alternatives. Manufacturer savings programs are more established. For patients without coverage, the cash-price gap between semaglutide and tirzepatide can be meaningful. The medication that’s actually accessible is the medication that actually works.
Evidence: Strong · Real-world access dataSemaglutide vs Tirzepatide.
The two leading GLP-1-class medications in 2026. They share mechanisms, but the differences are clinically meaningful — and the right choice depends on your specific situation.
Semaglutide
Ozempic · Wegovy · Rybelsus
Single-receptor agonist (GLP-1). Longest track record. Approved 2017 (Ozempic) and 2021 (Wegovy for weight loss). Wegovy HD 7.2 mg approved 2026.
- Strongest evidence base across cardiovascular and metabolic endpoints
- Often the first-line choice when starting GLP-1 therapy
- Generally well-tolerated; GI side effects common during titration
- Manufacturer savings programs often more accessible
Tirzepatide
Mounjaro · Zepbound
Dual-receptor agonist (GIP + GLP-1). Approved 2022 for diabetes; 2023 for weight management; 2026 for sleep apnea in obesity.
- Greatest absolute weight loss in head-to-head SURMOUNT trials
- Often more effective for patients who plateaued on semaglutide
- Some patients tolerate it better; others find it harder
- Newer indications expanding (sleep apnea in obesity, others under review)
Semaglutide is a tool. Foundations are the work.
Clinical trial data is impressive. Real-world long-term outcomes depend heavily on what you build alongside the medication — sleep, training, nutrition, and stress management. We treat that work as part of the program, not as fine print.
The medication makes the work possible. It doesn’t replace it.
Semaglutide reduces appetite and slows gastric emptying. For many patients, food preoccupation drops dramatically within the first 4–6 weeks. That creates an opening. What fills that opening determines whether the results last beyond the prescription — including what happens when you eventually taper off.
- Adequate protein intake to preserve lean mass during weight loss
- Daily movement — walking counts, and consistency beats intensity
- Sleep, stress, and alcohol — magnified metabolically when calories drop
- An exit plan from day one, whether you taper or stay on therapy long-term — discussed openly during our metabolic reset program
From consultation to first injection, in real medicine.
Semaglutide prescribing follows the same clinical pattern as any other thoughtful prescribing decision — proper workup first, then a decision based on what your labs and history actually show.
Initial consultation
In person at our Houston clinic. We discuss your full medical history, what you’ve tried, current weight and metabolic picture, family history of thyroid and pancreatic conditions, and whether semaglutide is the right fit — or whether tirzepatide is a better starting point for your situation. No prescription written this day.
Comprehensive lab work
A full metabolic workup at LabCorp or Quest near you — A1c, fasting insulin, lipid panel, comprehensive metabolic panel, thyroid (TSH, free T4), inflammatory markers, and any indication-specific testing. Pancreatic and thyroid contraindication screening included.
Protocol design
Your physician designs your protocol — starting dose, titration schedule, and target maintenance dose based on your specific picture. We discuss insurance coverage, manufacturer savings, what to expect through dose escalation, and how we’ll measure progress beyond the scale.
First prescription
FDA-approved Wegovy or Ozempic filled at retail pharmacy. Injection training (once-weekly subcutaneous, pre-filled pen), titration schedule (starting at 0.25 mg with monthly increases), and clear expectations: most patients notice appetite changes within 1–2 weeks; meaningful weight loss starts at 4–8 weeks.
Monitor & adjust
Monthly check-ins through titration, then every 3 months at maintenance dose. We repeat labs at 3 and 6 months. Dose adjustments based on response and tolerability. We have honest conversations about plateaus, side effects, switching to tirzepatide if needed, and the eventual decision about long-term continuation vs taper.
Ready to start the conversation?
A 45-minute consultation with one of our physicians. We’ll review your situation and decide together whether semaglutide is the right starting point — or whether tirzepatide, lifestyle medicine, or something else makes more sense first.
What semaglutide can — and can’t — do.
The evidence for semaglutide in weight management is strong. The gap between what well-prescribed semaglutide delivers and what the internet promises is still substantial. Here’s what to realistically expect.
What semaglutide does well
- Meaningful, sustained weight loss for most patients (mean ~15% at 2.4 mg, ~21% at 7.2 mg over 68–72 weeks)
- Reduced major adverse cardiovascular events in patients with established CV disease (SELECT trial)
- Improves A1c, fasting glucose, and insulin sensitivity in metabolically dysfunctional patients
- Reduces food preoccupation and “food noise” for most patients within the first month
- Longest safety record in the GLP-1 class — most predictable side effect profile
- Often more accessible via insurance than tirzepatide
What it can’t do
- Replace strength training, sleep, protein intake, or stress management
- Be appropriate for patients with personal or family history of medullary thyroid carcinoma or MEN2
- Be a fit for patients with severe gastroparesis, active pancreatic disease, or pregnancy
- Match tirzepatide’s absolute weight loss in head-to-head comparison (~5 percentage points behind)
- Continue indefinitely without periodic reassessment of need, tolerability, and exit strategy
- Prevent weight regain on its own — the STEP 1 extension showed ~2/3 of lost weight returns within 1 year of stopping without intervention
Before you book.
How much does semaglutide cost in Houston?
The initial consultation is $349. FDA-approved Wegovy and Ozempic cost varies significantly by insurance coverage. With commercial insurance and manufacturer savings programs, monthly out-of-pocket is often $25–$100. Without coverage, list price runs $1,000–$1,350/month, though manufacturer cash-pay programs have brought that to $499/month at Novo Nordisk’s NovoCare Pharmacy as of 2025. Our ongoing program fees cover physician oversight, lab review, and structured monitoring — separate from medication costs.
Should I start with semaglutide or tirzepatide?
For most patients starting GLP-1 therapy, semaglutide is the appropriate first-line choice — broader insurance coverage, longer safety record, and substantial efficacy. Tirzepatide is often the right choice for patients who need greater absolute weight loss, who have plateaued on semaglutide, or who have specific clinical reasons (such as the new sleep apnea indication). We make this decision during consultation based on your specific situation.
What’s the difference between Ozempic and Wegovy?
Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes (max dose 2.0 mg/week); Wegovy is FDA-approved for chronic weight management (doses up to 2.4 mg, and now 7.2 mg with Wegovy HD approved March 2026). The medication is the same molecule. For weight management, Wegovy is the on-label choice. Off-label use of Ozempic for weight loss has been common but is increasingly being limited by insurers.
Will I regain the weight if I stop?
The STEP 1 extension trial showed that patients who stopped semaglutide without continued lifestyle support regained approximately two-thirds of their lost weight within one year. This is one of the most important honest conversations to have at the start of treatment — not at the end. Many patients can transition to a lower maintenance dose, taper gradually, or continue indefinitely. We discuss exit strategy from day one as part of our metabolic reset program.
What about compounded semaglutide?
Compounded semaglutide became widely available during FDA-declared shortages and remains common in cash-pay clinics. The FDA’s official position changed in 2024-2025 as branded supply normalized. We work primarily with FDA-approved branded semaglutide for the simple reason that the quality control, dosing accuracy, and safety profile are well-established. If cost is the primary barrier, we’d rather have an honest conversation about manufacturer savings programs, tirzepatide alternatives, or generic alternatives like phentermine than route around regulated supply.
What are the most common side effects?
Gastrointestinal — nausea, constipation, diarrhea, and a feeling of fullness — affect most patients during dose escalation. These typically diminish within 2–4 weeks at each dose level. Slow titration (the standard 16-week escalation schedule) is the most important variable in tolerability; pushing the dose faster causes more side effects without faster results. Less common: fatigue, headache, injection site reactions. Rare: pancreatitis, gallstones, hypoglycemia (in patients also on insulin or sulfonylureas).
Do you accept insurance?
FDA-approved semaglutide is often covered by insurance for both diabetes (Ozempic) and weight management with BMI ≥30 or ≥27 with comorbidities (Wegovy). Our clinical service fees ($349 initial consultation; ongoing program fees) cover physician oversight, lab review, and structured monitoring — separate from medication costs. We don’t bill insurers directly but can provide documentation suitable for HSA/FSA submission and out-of-network reimbursement.
Start with a conversation, not a prescription.
A 45-minute consultation with one of our Houston physicians. We’ll review your situation, decide together whether semaglutide is the right starting point, and what comes next.